Initial pharmacotherapy for ST-segment elevation myocardial infarction

Slides:

Advertisements

Similar presentations

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 53 Management of ST-Elevation Myocardial Infarction.

Advertisements

The INT egrelin and E noxaparin R andomized assessment of A cute C oronary syndrome Treatment T rial Sponsored by the Canadian Heart Research Centre, Key.

The Impact of For-Profit Hospital Status on the Care and Outcomes of Patients with NSTEMI: Results From CRUSADE Bimal R. Shah, MD, Seth W. Glickman, MD,

Rationale for the Clinical Evaluation of Combination GP IIb-IIIa Inhibitor and Low-Dose Fibrinolytic Therapy in ST-Elevation Myocardial Infarction.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Comprehensive Meta-Analysis of Safety and Efficacy.

Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Crushed Prasugrel Tablets in Patients With STEMI.

Date of download: 7/11/2016 Copyright © The American College of Cardiology. All rights reserved. From: Small molecule glycoprotein IIb/IIIa receptor inhibitors.

Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Public Reporting for Percutaneous.

From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:

International Psychopharmacology Algorithm Project (IPAP) generalized anxiety disorder (GAD) algorithm flowchart. Yellow, first-line treatment (nodes 3–6);

Source: Saseen JJ, MacLaughlin EJ. Hypertension

The predominant types of vascular access for chronic dialysis patients are (A) the arteriovenous fistula and (B) the synthetic arteriovenous forearm graft.

Algorithm for the pharmacotherapy of social anxiety disorder

Algorithm for the management of increased ICP

The American College of Cardiology Presented by Dr. Adnan Kastrati

(CCTA, computed coronary tomography angiography; CMR, cardiac magnetic resonance; ECG, electrocardiogram; Echo, echocardiography; IHD, ischemic heart disease;

Algorithm for management of anemia of CKD in adults

Calculation of an adult parenteral nutrition (PN) regimen

Treatment approaches for Crohn disease. (Adapted from Hemstreet BA

Algorithm for preoperative management of patients taking antiplatelet therapy. ACS, acute coronary syndrome; BMS, bare metal stent; DES, drug-eluting stent;

Guidelines for the Management of Patients With ST- Elevation Myocardial Infarction Adapted from Focused Updates: ACC/AHA 2009.

Gompertzian kinetics tumor-growth curve: relationship to symptoms, diagnosis, and various treatment regimens. (Reproduced with permission from Buick RN.

Proper use of a metered-dose inhaler (MDI)

Algorithm for pain management in oncology patients

Algorithm for the treatment of atrial fibrillation (AF) and atrial flutter. (BB, β-blocker; CCB, calcium channel blocker [i.e., verapamil or diltiazem];

Dopamine metabolism results in hydrogen peroxide (H2O2) formation

Morphologically, pathogenic fungi can be grouped as either filamentous molds or unicellular yeasts. Molds grow as multicellular branching, thread-like.

Management of ST-Elevation Myocardial Infarction

Guidelines for the evaluation and management of a patient who presents with dyspeptic or ulcer-like symptoms. (COX-2, cyclooxygenase-2; GERD, gastroesophageal.

Management of an elevated INR in patients taking warfarin

Nodules are palpable, solid, round, or ellipsoidal lesions

Initial pharmacotherapy for ST-segment elevation myocardial infarction

Signs and symptoms of anorexia nervosa and bulimia nervosa

Pathogenesis of CKD-MBD and renal osteodystrophy

Illustration of the concept of peak concentration to the minimum inhibitory concentration (MIC) ratio for aminoglycosides. The MIC for the given organism.

Pathogenesis of systemic lupus erythematosus (SLE)

Normal glomerular autoregulation serves to maintain intraglomerular capillary hydrostatic pressure, glomerular filtration rate (GFR), and, ultimately,

Algorithm for the treatment of AF and AFl

Proposed use of P2Y12 inhibitors

Diagram representing the renin–angiotensin–aldosterone system

Treatment algorithm for adult cardiopulmonary arrest: advanced cardiac life support (ACLS) Source: Chapter 18. Cardiac Arrest, Pharmacotherapy: A Pathophysiologic.

Sickle cell gene inheritance scheme for one parent with sickle cell trait (SCT) and one parent with no sickle cell gene. Possibilities with each pregnancy:

Ischaemic Heart Disease Acute Coronary Syndrome

Diagram of the placement of a peritoneal dialysis catheter through the abdominal wall into the peritoneal cavity. (From Sowinski KM, Churchwell MD, Decker.

Mechanism of underlying elevated sodium chloride levels in the sweat of patients with cystic fibrosis (CF). Sweat ducts (Panel A) in patients with CF differ.

A. Wheals are rounded or flat-topped papules or plaques that are characteristically evanescent, disappearing within hours. An eruption consisting of wheals.

Algorithm for guideline-directed medical therapy for patients with SIHD. Colors correspond to the class of recommendations in the ACCF/AHATable The.

R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R

Glenn N. Levine et al. JACC 2016;68:

Glenn N. Levine et al. JACC 2016;68:

Chapter 28 Management of Patients With Coronary Vascular Disorders

The following slides are based on a presentation at a Satellite Symposium in association with the Annual Cardiovascular Conference at Lake Louise, Alberta,

Section F: Clinical guidelines

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

% Heparin + GPI IIb/IIIa Bivalirudin +

Measure-specific reasons for exclusion (2010-Q4–2013-Q3).

Nat. Rev. Cardiol. doi: /nrcardio

OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)

Giuseppe Gargiulo et al. JACC 2018;71:

Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 2: ST-Segment Elevation.

Any, acute and subacute stent thrombosis with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction.

Major bleeding with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction (STEMI) studies; (A) glycoprotein.

Effect of Additional Temporary Glycoprotein IIb-IIIa Receptor Inhibition on Troponin Release in Elective Percutaneous Coronary Interventions After Pretreatment.

Leslee J. Shaw et al. JIMG 2010;3:

A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.

Major bleeding with bivalirudin versus unfractionated heparin (UFH) in predominantly non-ST segment elevation acute coronary syndrome (NSTE-ACS) studies;

Propensity score-matching

Use of evidence-based cardiac medications before, during and after hospitalisation for the index event in (A) overall ACS population and (B) patients with.

R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Presentation transcript:

Initial pharmacotherapy for ST-segment elevation myocardial infarction Initial pharmacotherapy for ST-segment elevation myocardial infarction. aFor at least 48 hours. bSee Table 7-2 for dosing and specific types of patients who should not receive enoxaparin. cFor the duration of hospitalization, up to 8 days. dFor selected patients, see Table 7-2. eIf pretreated with UFH, stop UFH infusion for 30 minutes prior to administration of bivalirudin (bolus plus infusion). fIncreased risk of major bleeding and intracranial hemorrhage if a GP IIb/IIIa inhibitor is added to an anticoagulant for PCI following fibrinolysis, especially in the elderly; weight risk versus benefit. (ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; GP, glycoprotein; NTG, nitroglycerin; PCI, percutaneous coronary intervention; Subcut, subcutaneous; SL, sublingual; UFH, unfractionated heparin.) (Modified with permission from Spinler SA. Evolution of antithrombotic therapy used in acute coronary syndromes. In: Richardson MM, Chant C, Cheng JWM, et al., eds. Pharmacotherapy Self-Assessment Program. Book 1: Cardiology, 7th ed. Lenexa, KS: American College of Clinical Pharmacy, 2010.) Source: Chapter 7. Acute Coronary Syndromes, Pharmacotherapy: A Pathophysiologic Approach, 9e Citation: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L. Pharmacotherapy: A Pathophysiologic Approach, 9e; 2014 Available at: http://accesspharmacy.mhmedical.com/DownloadImage.aspx?image=/data/books/dipi9/dipi9_c007f002.png&sec=48820452&BookID=689&ChapterSecID=48811456&imagename= Accessed: November 09, 2017 Copyright © 2017 McGraw-Hill Education. All rights reserved